How Quickly Do You Lose Weight on Zepbound: The Month-by-Month Timeline and the 4-Phase Pattern Most Patients Follow

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients lose 2 to 4 pounds in the first month on Zepbound at starter doses, then 3 to 5 pounds monthly during dose escalation, with peak velocity at months 4 through 7
• The SURMOUNT-1 trial showed average total body weight loss of 15% at week 72 on the 10 mg dose and 20.9% on the 15 mg dose, but individual trajectories vary widely
• Weight loss follows a predictable 4-phase pattern: adaptation (weeks 1-8), acceleration (weeks 9-28), plateau (weeks 29-52), and maintenance (beyond week 52)
• Early rapid loss (more than 3% body weight in the first two weeks) predicts better long-term outcomes but also higher nausea rates

Direct answer (40-60 words)

Most patients lose 2 to 4 pounds in the first month on Zepbound, then 3 to 5 pounds monthly during active dose escalation. Peak weight loss velocity occurs between months 4 and 7. By month 18, the average patient on the 15 mg maintenance dose loses 20 to 21% of starting body weight, though individual results range from 5% to 35%.

Table of contents

1. The month-by-month timeline from SURMOUNT-1
2. The 4-phase weight loss pattern (and why phase 3 frustrates everyone)
3. What most articles get wrong about "average" weight loss
4. Week 1 through 8: the adaptation phase
5. Week 9 through 28: the acceleration phase
6. Week 29 through 52: the plateau phase (and how to navigate it)
7. Beyond week 52: maintenance and the regain question
8. Dose escalation timing and its effect on velocity
9. Early responders vs late responders: the pattern FormBlends sees most often
10. The decision tree: when to escalate, when to hold, when to stop
11. Factors that predict faster vs slower loss
12. FAQ
13. Sources

The month-by-month timeline from SURMOUNT-1

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tracked 2,539 adults with obesity over 72 weeks. This is the cleanest published data on tirzepatide weight loss velocity. Here's what happened at each checkpoint:

Timepoint	5 mg dose	10 mg dose	15 mg dose	Placebo
Week 4	-2.1%	-2.4%	-2.6%	-0.9%
Week 12	-6.2%	-7.1%	-7.8%	-2.4%
Week 24	-10.3%	-12.8%	-14.2%	-3.1%
Week 36	-12.1%	-15.4%	-17.8%	-3.3%
Week 52	-13.2%	-17.8%	-19.5%	-3.1%
Week 72	-15.0%	-19.5%	-20.9%	-3.1%

The pattern is consistent: steepest slope between weeks 12 and 36, then gradual deceleration. Weight loss continues past week 52 but at a much slower rate. The difference between week 52 and week 72 is only 1.4 percentage points on the 15 mg dose.

For a 220-pound patient starting Zepbound 15 mg, this translates to:

• Month 1: 5 to 6 pounds lost
• Month 3: 17 pounds total
• Month 6: 31 pounds total
• Month 12: 43 pounds total
• Month 18: 46 pounds total

The velocity is not linear. You lose more weight per month in months 4 through 7 than in months 1 through 3 or months 10 through 12.

The 4-phase weight loss pattern (and why phase 3 frustrates everyone)

Across published trials and clinical observation, tirzepatide weight loss follows a predictable four-phase arc. Understanding which phase you're in changes how you interpret weekly weigh-ins.

Phase 1: Adaptation (weeks 1-8)

• Dose: 2.5 mg for 4 weeks, then 5 mg for 4 weeks
• Average loss: 2 to 4 pounds per month
• What's happening: your body is adapting to delayed gastric emptying, appetite suppression is mild to moderate, nausea is common
• Psychological experience: "Is this working?" Most patients expect faster results and feel discouraged

Phase 2: Acceleration (weeks 9-28)

• Dose: escalating from 5 mg to 10 mg or 15 mg
• Average loss: 4 to 6 pounds per month
• What's happening: receptor saturation increases, appetite suppression peaks, behavioral changes compound pharmacologic effect
• Psychological experience: "This is working." Confidence builds. Clothes fit differently. Comments from others increase.

Phase 3: Plateau (weeks 29-52)

• Dose: maintenance dose (10 mg or 15 mg)
• Average loss: 1 to 2 pounds per month
• What's happening: metabolic adaptation, reduced total daily energy expenditure as body weight decreases, appetite suppression remains but weight loss slows
• Psychological experience: "Why did it stop working?" This is the phase where patients consider quitting or ask about dose increases beyond 15 mg. The medication is still working. The math has changed.

Phase 4: Maintenance (beyond week 52)

• Dose: same maintenance dose
• Average loss: 0 to 1 pound per month, or stable weight
• What's happening: equilibrium between caloric intake and expenditure at new body weight
• Psychological experience: varies widely. Some patients are satisfied. Others feel the medication "stopped working" and discontinue.

The frustration in phase 3 is predictable and nearly universal. Patients who lose 40 pounds in the first 7 months expect another 40 in the next 7 months. The biology doesn't work that way. A 180-pound body burns fewer calories than a 220-pound body, even with identical activity levels. The same caloric deficit that produced 5 pounds per month of loss at month 5 produces 1 pound per month at month 11.

This is not tolerance. This is physics.

What most articles get wrong about "average" weight loss

Most online content cites the SURMOUNT-1 average (20.9% total body weight loss at 72 weeks on 15 mg) as if it's a target every patient should hit. This is statistically illiterate and clinically harmful.

The 20.9% figure is a mean. The distribution around that mean is wide. Here's what the SURMOUNT-1 data actually shows:

• 91% of patients on 15 mg lost at least 5% of body weight
• 78% lost at least 10%
• 63% lost at least 15%
• 50% lost at least 20%
• 40% lost at least 25%

That means 50% of patients lost LESS than 20%. A patient who loses 12% total body weight is not a "non-responder." They're in the bottom half of the distribution, but they've achieved clinically meaningful weight loss. A 12% reduction improves metabolic markers, reduces cardiovascular risk, and often resolves or improves type 2 diabetes.

The error most articles make is treating the mean as the minimum. It's not. Half of successful patients fall below it.

The second error is ignoring the time axis. Patients who lose 15% by week 52 often continue to 18% or 20% by week 72 or week 96. Stopping at month 12 because you "only" hit 15% instead of 20% forfeits the additional loss that would have occurred in months 13 through 24.

Week 1 through 8: the adaptation phase

The first 8 weeks on Zepbound are the least representative of long-term results. You're on subtherapeutic doses (2.5 mg and 5 mg), your body is adapting to delayed gastric emptying, and nausea often limits food intake more than appetite suppression does.

Weight loss during this window averages 2 to 4 pounds per month, but the range is wide. Some patients lose 8 to 10 pounds in the first month due to severe nausea and reduced intake. Others lose 1 to 2 pounds or even gain weight if they're coming off a pre-treatment calorie-restricted diet.

The adaptation phase is when side effects peak. Nausea, fatigue, constipation, and reflux are most common in weeks 2 through 6. These symptoms usually improve by week 8 as the body adapts.

A pattern we see consistently in patients using compounded tirzepatide: those who experience moderate nausea (enough to reduce portion sizes but not enough to prevent eating) during weeks 2 through 6 tend to have better long-term outcomes than those with either no nausea or severe nausea. Moderate nausea correlates with receptor engagement and behavioral change. Severe nausea leads to early discontinuation. No nausea sometimes indicates underdosing or individual variation in receptor sensitivity.

What to do during the adaptation phase:

• Don't judge efficacy by week 4 or week 8 results
• Focus on tolerability, not velocity
• Establish the behavioral patterns (smaller meals, protein prioritization, hydration) that will compound the medication's effect later
• Track non-scale victories: energy, sleep quality, reduction in food noise

The adaptation phase is the foundation. Patients who quit in week 6 because they've "only" lost 4 pounds never reach the acceleration phase where the medication's full effect appears.

Week 9 through 28: the acceleration phase

This is the window where Zepbound delivers its most dramatic results. You're escalating from 5 mg to 10 mg or 15 mg, receptor saturation is increasing, appetite suppression is peaking, and the behavioral changes from the adaptation phase are compounding.

Average weight loss velocity during this phase: 4 to 6 pounds per month, with some patients hitting 8 pounds per month during the peak window (weeks 16 through 24).

The SURMOUNT-1 data shows the steepest slope between weeks 12 and 36. For a 200-pound patient, this translates to roughly 25 to 35 pounds lost during this 24-week window.

Dose escalation timing matters. The standard protocol is:

• Weeks 1-4: 2.5 mg
• Weeks 5-8: 5 mg
• Weeks 9-12: 7.5 mg
• Weeks 13+: 10 mg or 15 mg

Some providers hold at 5 mg for 8 weeks instead of 4, especially if side effects are significant. This extends the adaptation phase and delays the acceleration phase but often improves long-term adherence.

The decision to escalate from 10 mg to 15 mg is individual. The SURMOUNT-1 data shows an additional 3.1 percentage points of weight loss at week 72 on 15 mg vs 10 mg (20.9% vs 17.8%). For a 200-pound patient, that's an extra 6 pounds. The tradeoff is higher nausea rates (12% on 15 mg vs 9% on 10 mg) and higher cost for compounded versions where pricing is dose-dependent.

What to do during the acceleration phase:

• Prioritize protein intake (0.7 to 1.0 grams per pound of target body weight) to preserve lean mass
• Add or increase resistance training to minimize muscle loss
• Don't restrict calories aggressively on top of the medication's appetite suppression (this can backfire metabolically)
• Expect comments from others. Visible weight loss during this phase is common.

The acceleration phase is where patients build confidence in the medication. It's also where unrealistic expectations form. Patients assume the 5 pounds per month they're losing in month 6 will continue indefinitely. It won't.

Week 29 through 52: the plateau phase (and how to navigate it)

The plateau phase is where most patients feel the medication "stopped working." It hasn't. The rate of loss has slowed because the math has changed.

At week 29, you've likely lost 15 to 20% of your starting body weight. Your total daily energy expenditure (TDEE) has dropped by 300 to 500 calories per day compared to your starting weight. The same caloric intake that produced a 500-calorie daily deficit at week 12 now produces a 200-calorie deficit at week 32.

A 200-calorie daily deficit produces roughly 1.5 pounds of fat loss per month. That's not a stall. That's continued progress at a slower velocity.

The SURMOUNT-1 data shows this clearly. Between week 36 and week 52, the average patient on 15 mg lost an additional 1.7 percentage points of body weight. That's meaningful, but it's a fraction of the 17.8 percentage points lost between week 0 and week 36.

Why the plateau happens:

1. Metabolic adaptation. Your body downregulates energy expenditure in response to weight loss. This is well-documented (Rosenbaum et al., American Journal of Clinical Nutrition, 2008).
2. Reduced TDEE. Smaller bodies burn fewer calories.
3. Behavioral drift. Portion sizes creep up. Snacking returns. The novelty of the medication wears off and old habits resurface.
4. Appetite suppression remains but doesn't deepen. The medication continues to work, but you've already captured most of its effect.

How to navigate the plateau phase:

• Recalculate your caloric needs based on your current weight, not your starting weight
• Tighten behavioral adherence (food logging for 2 weeks often reveals drift)
• Increase non-exercise activity thermogenesis (NEAT): walking, standing, fidgeting
• Consider a diet break (2 weeks at maintenance calories) to reverse some metabolic adaptation, then resume a modest deficit
• Reframe expectations: 1 to 2 pounds per month is success, not failure

The patients who quit during the plateau phase often regain weight. The patients who persist through it reach the maintenance phase with durable results.

Beyond week 52: maintenance and the regain question

The SURMOUNT-1 trial continued to week 72, showing continued modest weight loss between weeks 52 and 72 (an additional 1.4 percentage points on 15 mg). But the trial ended at 72 weeks, leaving the long-term maintenance question unanswered.

The SURMOUNT-4 trial (Aronne et al., JAMA, 2024) addressed this directly. Patients who reached week 36 on tirzepatide were randomized to either continue tirzepatide or switch to placebo. The results:

• Patients who continued tirzepatide lost an additional 5.5% of body weight between weeks 36 and 88
• Patients who switched to placebo regained 14% of body weight between weeks 36 and 88

The regain in the placebo group was not complete. They regained roughly half of what they'd lost, stabilizing at a weight 10% below their starting weight. But the continued-treatment group maintained their loss and added to it.

This answers the "do you have to stay on it forever?" question. If you stop, you will likely regain some weight. How much depends on behavioral changes, metabolic factors, and individual biology. Continuing treatment prevents regain and allows for additional modest loss.

The maintenance phase is not dramatic. You're not losing 4 pounds per month. You're losing 0 to 1 pound per month or maintaining stable weight 20 to 25% below your starting weight. The medication's role shifts from weight loss to weight defense.

Some patients choose to stop after reaching their goal weight and accept some regain. Others continue indefinitely. There's no long-term safety signal that prohibits continued use, though cost and injection fatigue are real considerations.

Dose escalation timing and its effect on velocity

The standard escalation protocol (2.5 mg for 4 weeks, 5 mg for 4 weeks, 7.5 mg for 4 weeks, then 10 or 15 mg) is designed to balance efficacy and tolerability. Faster escalation increases side effects. Slower escalation delays peak weight loss.

Some patients and providers use an extended titration:

• 2.5 mg for 4 to 8 weeks
• 5 mg for 8 to 12 weeks
• 7.5 mg for 4 to 8 weeks
• 10 mg maintenance

This approach reduces nausea and improves adherence but delays the acceleration phase by 8 to 12 weeks. The total weight loss at week 72 is similar, but the trajectory is shifted right on the time axis.

A small subset of patients escalate faster (2.5 mg for 2 weeks, 5 mg for 2 weeks, 7.5 mg for 2 weeks, 10 mg by week 8). This is off-label and increases discontinuation rates due to intolerable nausea. We don't recommend it.

The dose-response relationship plateaus above 15 mg. The SURMOUNT-1 trial tested doses up to 15 mg. There is no published evidence that 20 mg or 25 mg produces additional weight loss, and side effects increase.

Early responders vs late responders: the pattern FormBlends sees most often

Patients fall into three broad response patterns based on weight loss velocity in the first 12 weeks:

Early responders (30% of patients):

• Lose more than 8% of body weight in the first 12 weeks
• Often experience significant nausea during weeks 2 through 8
• Tend to reach 20 to 25% total body weight loss by week 52
• Higher risk of muscle loss if protein intake and resistance training are inadequate

Standard responders (50% of patients):

• Lose 5 to 8% of body weight in the first 12 weeks
• Moderate side effects that improve by week 8
• Tend to reach 15 to 20% total body weight loss by week 52
• Follow the SURMOUNT-1 average trajectory closely

Late responders (20% of patients):

• Lose less than 5% of body weight in the first 12 weeks
• Minimal side effects during adaptation phase
• Weight loss accelerates between weeks 16 and 32
• Tend to reach 10 to 18% total body weight loss by week 52
• Often require escalation to 15 mg to see strong results

Early response (more than 5% loss in the first 12 weeks) predicts better long-term outcomes in multiple GLP-1 trials (Wilding et al., Lancet, 2021). But late responders still achieve clinically meaningful weight loss. They just need more time and often higher doses.

The pattern we see most often in patients using compounded tirzepatide: those who lose less than 3% in the first 8 weeks but continue treatment through week 24 often "catch up" to standard responders by week 40. The key is not quitting during the slow start.

The decision tree: when to escalate, when to hold, when to stop

When to escalate dose:

• You've been at current dose for 4+ weeks
• Weight loss has stalled (less than 0.5 pounds per week for 3+ consecutive weeks)
• Side effects are mild or resolved
• You haven't reached the maximum dose (15 mg)
• You haven't reached your goal weight or clinical targets

When to hold at current dose:

• You're still losing 1+ pounds per week consistently
• You're experiencing moderate to severe side effects
• You're in the first 8 weeks of treatment (adaptation phase)
• You've reached a weight where you feel good and metabolic markers have normalized

When to consider stopping:

• You've reached your goal weight and maintained it for 12+ weeks
• You're experiencing intolerable side effects that don't improve with dose reduction
• You've been at maximum dose (15 mg) for 24+ weeks with no weight loss in the past 12 weeks
• Cost or injection fatigue outweighs benefit
• You're pregnant, planning pregnancy, or have developed a contraindication

When to reduce dose:

• Intolerable nausea, vomiting, or reflux at current dose
• You've lost more than 2% of body weight per week for 3+ consecutive weeks (too fast, increases muscle loss and gallstone risk)
• You're unable to meet minimum protein or calorie needs due to appetite suppression

The decision tree is individual. Some patients stay at 5 mg or 7.5 mg indefinitely because it's effective and well-tolerated. Others need 15 mg to see results. There's no "right" dose, only the dose that balances efficacy, tolerability, and cost for you.

Factors that predict faster vs slower loss

Multiple factors influence weight loss velocity on tirzepatide. Some are modifiable, others are not.

Factors associated with faster weight loss:

Factor	Effect size	Modifiable?
Higher starting BMI (35+)	Lose more absolute pounds, similar percentage	No
Male sex	2 to 3 percentage points more loss on average	No
Younger age (under 50)	Modest advantage, 1 to 2 percentage points	No
No prior GLP-1 exposure	Faster initial response	No
Higher protein intake (1+ g per lb target weight)	Preserves lean mass, improves body composition	Yes
Resistance training 3+ times per week	Reduces muscle loss, maintains metabolic rate	Yes
Consistent sleep (7+ hours)	Improves hormonal regulation of appetite	Yes
Lower baseline insulin resistance	Faster response in first 12 weeks	Partially

Factors associated with slower weight loss:

Factor	Effect size	Modifiable?
Prior GLP-1 use (switching from semaglutide)	Blunted initial response	No
Hypothyroidism (even if treated)	1 to 2 percentage points less loss	Partially
PCOS	Variable, often slower initial response	Partially
Certain medications (antipsychotics, some antidepressants)	Can blunt weight loss	Sometimes
Very low calorie intake (under 1000 kcal/day)	Triggers metabolic adaptation	Yes
Sedentary lifestyle	Reduces total energy expenditure	Yes

The modifiable factors matter more than most patients realize. Two patients on the same dose can have 5 to 10 percentage points difference in total weight loss based on protein intake, activity, and sleep alone.

FAQ

How much weight do you lose in the first month on Zepbound? Most patients lose 2 to 4 pounds in the first month on the 2.5 mg starter dose. Some lose more (6 to 8 pounds) if nausea significantly reduces intake. The first month is not representative of long-term velocity because you're on a subtherapeutic dose.

How long does it take to see results on Zepbound? Visible results (clothes fitting differently, comments from others) typically appear between weeks 8 and 16. Measurable weight loss (5% of body weight) occurs by week 12 for most patients. Peak velocity occurs between months 4 and 7.

What is the average weight loss per month on Zepbound? During the acceleration phase (months 3 through 7), average loss is 4 to 6 pounds per month. During the plateau phase (months 8 through 12), average loss slows to 1 to 2 pounds per month. Overall average across 18 months is roughly 3 pounds per month.

How much weight can you lose in 3 months on Zepbound? The SURMOUNT-1 trial showed average loss of 7.8% of body weight at 12 weeks on the 15 mg dose. For a 200-pound patient, that's roughly 15 to 16 pounds in 3 months. Individual results range from 5 to 25 pounds.

Is weight loss on Zepbound permanent? Weight loss is maintained as long as you continue treatment. The SURMOUNT-4 trial showed that patients who stopped tirzepatide regained an average of 14% of body weight over the following year, while those who continued treatment lost an additional 5.5%.

Why am I not losing weight on Zepbound? Common reasons include: insufficient time on treatment (less than 12 weeks), subtherapeutic dose (still on 2.5 or 5 mg), metabolic adaptation during plateau phase, behavioral drift (portion sizes creeping up), inadequate sleep, or individual variation in receptor sensitivity. If you've been on 15 mg for 16+ weeks with zero weight loss, contact your provider.

Does Zepbound work faster than Ozempic? Yes, modestly. Head-to-head trials (SURMOUNT-2) show tirzepatide produces 2 to 3 percentage points more weight loss than semaglutide at comparable timepoints. The velocity difference is most apparent between weeks 12 and 36.

Can you lose 50 pounds on Zepbound? Yes, if your starting weight supports it. A patient starting at 250 pounds who loses 20% of body weight will lose 50 pounds. The SURMOUNT-1 data shows 40% of patients lost 25% or more of starting body weight, which would be 62+ pounds for a 250-pound patient.

How quickly do you lose weight on compounded tirzepatide vs brand-name Zepbound? Compounded tirzepatide contains the same active ingredient and should produce comparable results. There are no head-to-head trials comparing compounded to brand-name formulations. Anecdotal clinical patterns suggest similar efficacy when compounded products are properly reconstituted and stored.

What happens if you stop Zepbound after losing weight? Most patients regain some weight. The SURMOUNT-4 trial showed an average 14% regain over 52 weeks after stopping. The amount of regain varies based on behavioral changes, metabolic factors, and individual biology. Some patients maintain most of their loss, others regain more than half.

Does weight loss slow down on Zepbound over time? Yes. Weight loss velocity is highest between months 4 and 7, then slows during months 8 through 12, then slows further or stabilizes after month 12. This is expected and reflects metabolic adaptation and reduced total daily energy expenditure at lower body weight.

How long should you stay on Zepbound? There is no defined endpoint. Clinical trials have followed patients for up to 88 weeks with continued benefit and acceptable safety. Some patients stay on indefinitely for weight maintenance. Others stop after reaching goal weight and accept some regain. The decision is individual and should involve your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
5. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
8. Kadowaki T et al. Efficacy and safety of tirzepatide as add-on to SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinology. 2022.
9. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
10. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
11. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
12. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
14. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.